Quick Facts

• Intended Use: To provide a visual aid during specific surgical procedures.
• Therapeutic Domains: Urology and gynecology.
• Primary Action: Visualization of the ureters during cystoscopic assessment.

---

What Intigo Treats: Main Uses and Benefits

Intigo (indigotindisulfonate sodium injection) is a diagnostic dye used in adult patients to assist healthcare professionals during certain surgical procedures. The primary use of this agent is to serve as a visualization aid for the cystoscopic assessment of the ureters' integrity. This application is pertinent following specific urological and gynecological open, robotic, or endoscopic surgical procedures.

This medication is administered to help localize the ureteral orifices and confirm ureteral integrity following surgical intervention in the relevant anatomical areas. This visualization capability supports the management of potential complications related to ureteral function during or after complex procedures.

The official regulatory profile for Intigo (indigotindisulfonate sodium injection) defines the eligible population and conditions for its use as a diagnostic aid.

Populations and Conditions

Classification	Population or Condition
Contraindicated	Patients with known hypersensitivity to indigotindisulfonate or any of its components.
Recommended Use	Adult patients undergoing urological or gynecological surgical procedures where ureter integrity is assessed.
Not Recommended	Patients with severe renal impairment, defined as an estimated Glomerular Filtration Rate (eGFR) below 30 mL/min.

Age and Reproductive Status

Intigo is subject to critical restrictions based on age and physiological status. The safety and effectiveness have not been established in pediatric patients, resulting in a categorical exclusion for that population. Regarding reproductive status, the regulatory label states that the medicine should be given to a pregnant woman only if clearly needed. Similarly, caution should be exercised when administering Intigo to a nursing woman, reflecting its conditional status in these populations.

---

Connection to the overall eligibility profile

The regulatory documents establish the adult patient population as the eligible group in which the diagnostic use is indicated. Eligibility is then strictly limited by an absolute contraindication for hypersensitivity, a conditional exclusion based on severe renal function, and a use not established restriction for all pediatric patients.

Interactions with other medicines and products

The officially documented interaction profile for Intigo (Cinnarizine) is primarily structured around pharmacodynamic effects, which define necessary constraints on co-administration.

Pharmacodynamic Potentiation

Co-administration with other medicines that act on the central nervous system (CNS) may result in the potentiation of the sedative effects. This documented additive action applies to substance categories classified as CNS Depressants, including hypnotic agents, specific anxiolytics, opioid analgesics, and antipsychotic medicines. This additive effect is also formally noted when Intigo is used with Tricyclic Antidepressants. Furthermore, an additive antimuscarinic action is documented when co-administered with other antimuscarinic agents.

Procedural and Substance Constraints

A specific interaction occurs with certain diagnostic procedures: Cinnarizine should not be administered within four days prior to dermal reactivity tests (skin tests). This mandatory timing separation is required to prevent procedural interference that could lead to a false-negative result. A significant pharmacodynamic risk is the potential to mask the initial warning signs of damage caused by Ototoxic Drugs, such as aminoglycoside antibiotics. Regarding substances, consumption of alcoholic beverages should be avoided during treatment, as official labeling states that alcohol may potentiate the sedative effects. No major metabolic or transporter-based pharmacokinetic interactions that alter the systemic exposure of Cinnarizine are formally documented.

Intigo is an inhibitor of the RANKL-mediated signaling pathway. It functions by binding directly to the Receptor Activator of Nuclear Factor kappa B Ligand ( RANKL). This binding physically blocks RANKL from interacting with its cognate receptor, RANK (located on osteoclast precursors and mature osteoclasts).

This RANKL/RANK antagonism disrupts the intracellular signaling cascade necessary for osteoclastogenesis (the formation of new osteoclasts) and osteoclast survival. Altering this pathway modulation shifts the cellular balance, leading to a net decrease in the generation and function of bone-resorbing osteoclasts.

The consequent reduction in osteoclast activity results in decreased bone resorption. This physiological consequence is biochemically observable as lower levels of bone turnover markers (e.g., C-terminal telopeptide of type I collagen, or CTX) and a resultant change in bone mineral density.

Intigo is a diagnostic agent, indigotindisulfonate sodium injection, with a standardized use pattern defined for administration during specific surgical procedures. The method of delivery is a single, standardized intravenous (IV) injection, which is required for the diagnostic application. The standard adult dose is a volume of 5 mL, which corresponds to 40 mg of the active substance. This fixed dose is administered once per procedure and is not subject to titration based on clinical response.

The injection is administered into a vein over a precise period of 1 minute. Prior to administration, the solution must be visually inspected, and the contents are withdrawn using a 5 micron or smaller filter to manage particulate matter. The solution must not be diluted, and the contents of the single-dose ampule are used immediately, with any remainder discarded.

Usage is further constrained by specific population characteristics. While no dose adjustment is necessary for mild-to-moderate renal impairment, use of this agent is not recommended in patients who have severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL/min. Furthermore, the safety and effectiveness of Intigo have not been established for use in pediatric patients. Procedurally, monitoring of blood pressure and cardiac rhythm is required during and immediately following the injection.

Research Evidence / Overview of Studies for Intigo (Indigotindisulfonate Sodium)

The evidence supporting the use of Intigo was studied for its specific role as a diagnostic visualization aid during surgical procedures. Research examined how this dye was used to monitor the function of the urinary tract during and immediately following certain procedures.

Evidence for Use as a Visualization Aid in Surgery

Research examined Intigo in the context of exploring visualization patterns related to the ureters—the tubes that carry urine from the kidneys to the bladder—during cystoscopic assessment. This procedure is performed after specific urological or gynecological surgical procedures where research explored assessing the integrity and flow within the ureters.

These trials primarily included adult patients scheduled for procedures that required this specific assessment. The research explored measurements of visual contrast related to the dye's presence.

Study Design and Visualization Measurement

Studies explored this effect using randomized, controlled clinical trials. Researchers compared the visual patterns created by the dye injection against a control (saline) injection within the same patient, known as an intra-patient controlled design. This approach was used to assess the changes associated with the dye's presence.

The primary outcome monitored was the Conspicuity Score—a visual grading system. The research describes patterns where the Conspicuity Score measurements following the dye's presence were higher when compared to the saline control assessment. The studies monitored the time required for this blue color to become visible, which generally occurred within 4 to 9 minutes after the injection. These findings help contextualize how the dye was observed in the intraoperative setting.

Evidence in Special Populations

Subgroup analyses were monitored in adults who had mild to moderate reduced kidney function. The research describes that observations in this group were generally similar to those in patients with normal kidney function. However, the parameters for use and visualization have not been established in pediatric patients, meaning there is no information available regarding use in children.

Long-Term Follow-up and Research Gaps

Because Intigo serves as an immediate diagnostic tool, the study observations focused on the intraoperative period. There is limited information for long-term outcomes, as research was not designed to track durable effects or post-surgical recovery. Data for patients with severe renal impairment were not included in the main clinical trials, and there are no data available describing the visualization patterns in this specific patient population.

How to Store and Dispose of Intigo?

This section outlines the official, regulatory requirements for the storage, handling, and disposal of Intigo (indigotindisulfonate sodium injection) based on government-approved labeling.

Storage Condition	Official Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F). Do not refrigerate or freeze.
Light Protection	Store in the original carton to protect the solution from light.
Stability/Handling	Use immediately after opening the single-dose ampule. Prior to administration, filter the contents using a 5 micron or smaller filter.
Disposal	Discard any unused portion of the solution. Dispose of the product according to institutional or local pharmaceutical waste protocols for non-hazardous medicines.